duxup 6 hours ago

Biotech seems to historically require a lot of iterations / failures before breakthroughs happen.

I'm not sure the typical VC "startup" type expectations / speed really lends itself to that kind of business.

hoseyor 6 hours ago

I wonder if that was private lending/credit. There seems to be a huge issue building in that unregulated space.